Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

by Alegre, A., Bakker, N.A, Bladé, J., Cavo, M., Larocca, A., Laubach, J., Leleu, X., Maisel, C., Mateos, M.-V, Mazumder, A., Nadeem, O., Oriol, A., Orre, M., Paner, A., Raptis, A., Richardson, P.G, Rodriguez-Otero, P., Sandberg, A., Torrång, A., Touzeau, C.
Published 2022

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

by Avet-Loiseau, H., Bahlis, N.J, Cavo, M., Dimopoulos, M.A, Facon, T., Heuck, C., Hungria, V., Iida, S., Kobos, R., Krevvata, M., Kumar, S., Mateos, M.-V, Moreau, P., Munshi, N., Paiva, B., Perrot, A., Plesner, T., Qi, M., San-Miguel, J., Sonneveld, P., Spencer, A., Sun, S., Ukropec, J., Usmani, S.Z, van de Donk, N.W.C.J, Wang, J., Weisel, K.
Published 2022